Vincerx Pharma, Inc. Common Stock (VINC) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.01 (+0.00%), Market cap $0.00B, 52-week low–high $0.01 ~ $0.07.
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 dose-escalation study for relapsed/refractory acute myeloid leukemia, higher-risk MDS, and B-cell acute lymphoblastic leukemia; VIP236, an SMDC, which
Financial statements, price targets, institutional (13F) holdings and related news for Vincerx Pharma, Inc. Common Stock are updated in real time on BlackAll Trade.
Vincerx Pharma, Inc. Common Stock trades at $0.01 (+0.00%). Real-time quotes and charts are available on BlackAll Trade.
Vincerx Pharma, Inc. Common Stock has a market cap of about $0.00B.
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United St